Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03777267 · ClinicalTrials.gov registry record · NA
Cereset Research Exploratory Study
A NA study of Neurological Diseases or Conditions and Cardiovascular Conditions After Birth, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT03777267: Recruiting NA study of Neurological Diseases or Conditions and Cardiovascular Conditions After Birth, sponsored by Wake Forest University Health Sciences.
NCT03777267 is a NA study of Neurological Diseases or Conditions and Cardiovascular Conditions After Birth that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 200 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03777267, a NA study of Neurological Diseases or Conditions and Cardiovascular Conditions After Birth, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the use of Cereset Research to improve autonomic function in participants with symptoms of stress, anxiety, or insomnia.
Primary Outcome
Heart rate variability is measured in the time domain as standard deviation of beat-to-beat interval (SDNN, milliseconds). For calculation of SDNN, the R-R intervals are visually inspected, and data considered as artifact is manually removed. Heart rate are acquired from 10 minute recordings of noninvasive finger arterial pressure measurements and ECG with participants lying quietly, supine. Systolic BP and beat to beat, RR intervals files generated via the data acquisition system (BIOPAC acquis
Conditions Studied
Interventions
- DEVICE Active CR
Study Locations (1)
North Carolina
- Wake Forest University Health Scienc\ess - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2019-04-12 |
| Est. Completion | 2027-04 |
| Phase | NA |
What NCT03777267 shows while recruiting
NCT03777267 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower).
The record links to 3 conditions, with Neurological Diseases or Conditions appearing as the primary indexed condition, and to 1 intervention - of which Active CR is the first listed.
NCT03777267 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT03777267 about?
NCT03777267 is a clinical study titled "Cereset Research Exploratory Study". The purpose of this study is to evaluate the use of Cereset Research to improve autonomic function in participants with symptoms of stress, anxiety, or insomnia.
What is the current status of trial NCT03777267?
This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2019-04-12. Estimated completion is 2027-04.
What conditions does trial NCT03777267 study?
This clinical trial studies the following conditions: Neurological Diseases or Conditions, Cardiovascular Conditions After Birth, Psychophysiologic Disorders.
What interventions are being tested in trial NCT03777267?
The interventions under investigation include: Active CR (DEVICE).
Who is sponsoring clinical trial NCT03777267?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03777267 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03777267's enrollment target sits among peer trials
200 506th of 2000 higher than 1,435 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI